Pain Management in The Post-COVID Era—An Update: A Narrative Review Part 4
Sep 20, 2023
ACKNOWLEDGEMENTS
Funding. No funding or sponsorship was received for this study or publication of this article.
Cistanche can act as an anti-fatigue and stamina enhancer, and experimental studies have shown that the decoction of Cistanche tubulosa could effectively protect the liver hepatocytes and endothelial cells damaged in weight-bearing swimming mice, upregulate the expression of NOS3, and promote hepatic glycogen synthesis, thus exerting anti-fatigue efficacy. Phenylethanoid glycoside-rich Cistanche tubulosa extract could significantly reduce the serum creatine kinase, lactate dehydrogenase, and lactate levels, and increase the hemoglobin (HB) and glucose levels in ICR mice, and this could play an anti-fatigue role by decreasing the muscle damage and delaying the lactic acid enrichment for energy storage in mice. Compound Cistanche Tubulosa Tablets significantly prolonged the weight-bearing swimming time, increased the hepatic glycogen reserve, and decreased the serum urea level after exercise in mice, showing its anti-fatigue effect. The decoction of Cistanchis can improve endurance and accelerate the elimination of fatigue in exercising mice, and can also reduce the elevation of serum creatine kinase after load exercise and keep the ultrastructure of skeletal muscle of mice normal after exercise, which indicates that it has the effects of enhancing physical strength and anti-fatigue. Cistanchis also significantly prolonged the survival time of nitrite-poisoned mice and enhanced the tolerance against hypoxia and fatigue.
Click on Over fatigue
【For more info:george.deng@wecistanche.com / WhatsApp:8613632399501】
Author's Contributions. Salah N. El-Tallawy (Corresponding Author): concept and design, writing, searching, supervision for all steps. Joseph V. Perglozzi: design, editing, and revision of the final draft. Rania S. Ahmed: searching, study screening, editing. Abdullah M. Kaki: revision of final draft, editing. Mohamed S. Nagiub: searching, study screening, editing. JoAnn K LeQuang: design, editing, and revision of the final draft. Mamdouh M.M. Haddarah: revision of the final draft.
Disclosure. All authors declare no conflicts of interest.
Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Data Availability. Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.
Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any noncommercial use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
REFERENCES
1. World Health Organization: COVID-19 Weekly epidemiological update on COVID-19 January 2023. Edition 124.
2. Muller JE, Nathan DG. COVID-19, nuclear war, and global warming: lessons for our vulnerable world. Lancet. 2020;395(10242):1967–8.
3. Norton A, Olliaro P, Sigfrid L, Carson G, Hastie C, Kaushic C, et al. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. Lancet Infect Dis. 2021;21(5):601–2.
4. Berger Z, Evans N, Phelan A, Silverman R. COVID-19: control measures must be equitable and inclusive. BMJ. 2020.
5. World Health Organization World Health Statistics, COVID-19. Geneva 2021.
6. Martelletti P, Bentivegna E, Spuntarelli V, Luciani M. Long-COVID headache. SN Compr. Clin Med. 2021;3(8):1704–6.
7. O’Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long COVID among hospitalized and non-hospitalized populations: a systematic review and meta-analysis. Clin Med. 2023;55: 101762.
8. Global, regional, and national disability-adjusted life years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1859–922.
9. El-Tallawy SN, Nalamasu R, Pergolizzi JV, Gharibo C. Pain management during the COVID-19 pandemic. Pain Ther. 2020;9:453–66.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.
11. National Institute for Health and Care Excellence, Practitioners RC of G, Scotland HI. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guidel; 2020:1–35.
12. Khoja O, Passadouro BS, Mulvey M, Delis I, Astill S, Tan AL, Sivan M. Clinical characteristics and mechanisms of musculoskeletal pain in long COVID. J Pain Res. 2022;15:1729–48.
13. Emergency use of ICD codes for COVID-19 disease outbreak. Found in: International Definitions of Diseases 11th Revision ICD-11 (who. int)
14. NHS England and NHS Improvement website information on Long COVID.
15. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38(1):1–211
16. Puntillo F, Giglio M, Brienza N, Viswanath O, Urits I, Kaye AD, Pergolizzi J, Paladini A, Varrassi G. Impact of COVID-19 pandemic on chronic pain management: looking for the best way to deliver care. Best Pract Res Clin Anaesthesiol. 2020;34: 529–37.
17. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157:1382–6.
18. Marinangeli F, Giarratano A, Petrini F. Chronic pain and COVID-19: pathophysiological, clinical and organizational issues. Minerva Anestesiol. 2021;87: 828–32.
19. Pan American Health Organization. Framework for the Implementation of a Telemedicine Service. Washington DC, PAHO 2016.
20. Wadehra S. COVID long haulers and the new chronic pain profile. Pract Pain Manag. 2022;22(1).
21. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesthesia. 2020;125(4):436–49.
22. Ghai B, Malhotra N, Bajwa SJ. Telemedicine for chronic pain management during the COVID-19 pandemic. Indian J Anaesth. 2020;64:456–62.
23. Lin I, Wiles L, Waller R, Goucke R, Nagree Y, Gibberd M, Straker L, Maher C, O’Sullivan P. What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: a systematic review. Br J Sports Med. 2020;54:79–86.
24. Pascarella G, Strumia A, Piliego C, Bruno F, del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206.
25. El-Tallawy SN, Titi MA, Ejaz AA, Abdulmomen A, Elmorshedy H, Aldammas F, Baaj J, Alharbi M, Alqatari A. Prevalence and risk factors associated with mental health symptoms among anesthetists in Saudi Arabia during the COVID-19 pandemic. Int J Ment Health. 2022;51(4):448–69.
26. Hong SM, Park YW, Choi EJ. Steroid injections in pain management: influence on coronavirus disease 2019 vaccines. Korean J Pain. 2022;35(1):14–21.
27. Tana C, Bentivegna E, Cho SJ, et al. Long COVID headache. J Headache Pain. 2022;23:93.
28. Song XJ, Xiong DL, Wang ZY, et al. Pain management during the COVID-19 pandemic in China: lessons learned. Pain Med. 2020;21(7):1319–23.
29. Zis P, Ioannou C, Artemiadis A, Christodoulou K, Kalampokini S, Hadjigeorgiou GM. Prevalence and determinants of chronic pain post-COVID; crosssectional study. J Clin Med. 2022;11:5569.
30. Clauw DJ, Ha¨user W, Cohen SP, Fitzcharles MA. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020;161: 1694–7.
31. Karos K, McParland JL, Bunzli S, Devan H, Hirsh A, Kapos FP, Keogh E, Moore D, Tracy LM, AshtonJames CE. The social threats of COVID-19 for people with chronic pain. Pain. 2020;161:2229–35.
32. Soares FHC, Kubota GT, Fernandes AM, et al. Prevalence and characteristics of new-onset pain in COVID-19 survivors, a controlled study. Eur J Pain. 2021;25:1342–54.
33. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anaheim M, Meziani F. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–70.
34. Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16–27 (e1).
35. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–90.
36. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77:1018–27.
37. Kemp HI, Laycock H, Costello A, Brett SJ. Chronic pain in critical care survivors: a narrative review. Br J Anaesthesia. 2019;123(2):e372–84.
38. Zis P, Loannou C, Artemiadis A, Christodoulou K, Kalampokini S, Hadjigeorgiou GM. Prevalence and determinants of chronic pain post-COVID; Crosssectional study. J Clin Med. 2022;11:5569.
39. Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. Crit Care. 2010;14:R6.
40. Puntillo KA, Max A, Chaize M, Chanques G, Azoulay E. Patient recollection of ICU procedural pain and post ICU burden: the memory study. Crit Care Med. 2016;44:1988–95.
41. Ferna´ndez-de-las-Pen˜as C, Palacios-Cen˜a D, Go´mezMayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55–70.
42. Ferna´ndez-de-las-Pen˜as C, Navarro-Santana M, Plaza-Manzano G, Palacios-Cen˜a, Arendt-Nielsen L. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infections: a systematic review and meta-analysis. Pain. 2022;163:1220–31.
43. Ferna´ndezdelas-Pen˜as C, de-la-Llave-Rinco´na A, Ortega-Santiagoa R, et al. Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors: a multicenter study. Pain. 2022;163: e989–96.
44. Lovell N, Maddocks M, Etkind SN, et al. Characteristics, symptom management, and outcomes of 101 patients with COVID-19 referred for hospital palliative care. J Pain Symptom Manage. 2020;60(1): E77–81.
45. Fernandez-de-Las-Penas C, Navarro-Santana M, Gomez-Mayordomo V, Cuadrado ML, GarciaAzorin D, Arendt-Nielsen L, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 2021;28(11):3820–5.
46. Kisiela MA, Janols H, Nordqvist T, Bergquist J, Hagfeldt S, Malinovschi A, Svartengren M. Predictors of post-COVID-19 and the impact of persistent symptoms in non-hospitalized patients 12 months after COVID-19, with a focus on workability. Upsala J Med Sci. 2022;127: e8794.
47. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth. 2020;125(4):440–3.
48. El-Tallawy SN, Nalamasu R, Salem GI, LeQuang JK, Pergolizzi JV, Christo PJ. Management of musculoskeletal pain: an update with emphasis on chronic musculoskeletal pain. Pain Ther. 2021;10:181–209.
49. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China JAMA Neurol. 2020;77(6):683–90.
50. Gustafson OD, Rowland MJ, Watkinson PJ, McKechnie S, Igo S. Shoulder impairment following critical illness: a prospective cohort study. Crit Care Med. 2018;46(11):1769–74.
51. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021.
52. Arca KN, Starling AJ. Treatment-refractory headache in the setting of COVID-19 pneumonia: migraine or meningoencephalitis? Case report. SN Comprehensive Clin Med. 2020;2(8):1200–3.
53. Goettler CE, Pryor JP, Reilly PM. Brachial plexopathy after prone positioning. Crit Care. 2002;6: 540–2.
54. Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med. 2003;31:1012–6.
55. Afari N, Ahumada SM, Wright LJ, Mostoufi S, Golnari G, Reis V, Cuneo JG. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med. 2014;76:2–11.
56. Pierce JD, Shen Q, Cintron SA, Hiebert JP. PostCOVID-19 syndrome. Nurs Res. 2022;71(2):164–74.
57. Wadehra S. COVID long haulers and the new chronic pain profile. Pract Pain Manag. 2022;22(1).
58. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15.
59. Kelly-Davies G. Why COVID infections leave some patients in chronic pain. Pain News Network. 2021.
60. Martı´n MTF, Solo´rzano EO. COVID-19 and pain: what we know so far. Multidisciplinary Pain J. 2021;1:36–44.
61. Karaarslan F, Gu¨neri FD, Kardes¸ S. Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol. 2022;41(1):289–96.
62. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23:3–20.
63. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021:1–9.
64. McFarland AJ, Yousuf MS, Shiers S, Price TJ. Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain. Pain Report. 2021;6:e885.
65. Fernandez-de-Las-Penas C, Rodriguez-Jimenez J, Fuensalida-Novo S, et al. Myalgia as a symptom at hospital admission by SARS-CoV-2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. Pain. 2021.
66. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of post-acute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.
67. Fricton J. COVID-19 long-haulers trigger an increase in pain management needs.
68. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
69. Mutiawati E, Kusuma HI, Fahriani M, Harapan H, Syahrul S, Musadir N. Headache in post-COVID-19 patients: its characteristics and relationship with the quality of life. Medicina. 2022;58:1500.
70. Martelletti P, Bentivegna E, Luciani M, Spuntarelli V. Headache as a prognostic factor for COVID-19. Time to re-evaluate. SN Compr Clin Med. 2020;2(12):2509–10.
71. Pullen MF, Skipper CP, Hullsiek KH, Bangdiwala AS, Pastick KA, Okafor EC, Lofgren SM, Rajasingham R, Engen NW, Gladys A, Williams DA, Abbasi M, Boulware DR. Symptoms of COVID-19 outpatients in the United States. Open Forum Infect Dis. 2020;7(7):ofaa271.
72. Caronna E, Ballve A, Llaurado A, Gallardo VJ, Ariton DM, Lallana S, Lopez Maza S, Olive Gadea M, Quibus L, Restrepo JL, Rodrigo-Gisbert M, Vilaseca A, Hernandez Gonzalez M, Martinez Gallo M, Alpuente A, Torres-Ferrus M, Pujol Borrell R, Alvarez-Sabin J, Pozo-Rosich P. Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410–21.
73. Trigo J, Garcia-Azorin D, Planchuelo-Gomez A, Martinez-Pias E, Talavera B, Hernandez-Perez I, Valle-Penacoba G, Simon-Campo P, de Lera M, Chavarria-Miranda A, Lopez-Sanz C, Gutierrez-Sanchez M, Martinez- Velasco E, Pedraza M, Sierra A, Gomez-Vicente B, Arenillas JF, Guerrero AL. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. J Headache Pain. 2020;21(1):94.
74. Caronna E, Pozo-Rosich P. Headache as a symptom of COVID-19: narrative review of 1-year research. Curr Pain Headache Rep. 2021;25(11):73.
75. Ooi EE, Dhar A, Petruschke R, et al. Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. NPJ Vaccines. 2022;7:31.
76. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K, Sapey E, Calvert MJ, TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428–42.
77. Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain. 2010;11(1): 59–66.
78. Dono F, Consoli S, Evangelista G, D’Apolito M, Russo M, Carrarini C, et al. New daily persistent headache after SARS-CoV-2 infection: a report of two cases. Neurol Sci. 2021;42(10):3965–8.
79. Attala N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Report. 2021;9(6): e884.
80. Rodrı´guez Y, Vatti N, Ramı´rez-Santana C, Chang C, Mancera-Pa´ez O, Gershwin ME, Anaya JM. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8–37.
81. Stefano GD, Falco P, Galosi E, Di Pietro G, Leone C, Truini A. A systematic review and meta-analysis of neuropathic pain associated with coronavirus disease 2019. EJP. 2023;27(1):44–53.
82. Hruschak V, Flowers KM, Azizoddin DR, Jamison RN, Edwards RR, Schreiber KI. Cross-sectional study of psychosocial and pain-related variables among patients with chronic pain during a time of social distancing imposed by the coronavirus disease 2019 pandemic. Pain. 2021;162(2):619–29.
83. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, Glaser A, Elsayegh D. COVID-19 presenting as stroke. Brain Behav Immun. 2020;87: 115–9.
84. Bouhassira D, Chassany O, Gaillat J, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain. 2012;153: 342–9.
85. Ferreira ML, Albuquerque MFP, de Brito CAA, et al. Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurol. 2020;19:826–39.
86. Cherry CL, Wadley AL, Kamerman PR. Painful HIV-associated sensory neuropathy. Pain Manag. 2012;2: 543–52.
87. Finnerup NB, Attal N, Haroutounian S, Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpa¨a¨ M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73.
88. Moisset X, Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, LanteriMinet M, Lefaucheur JP, Mick G, Piano V, Pickering G, Piquet E, Regis C, Salvat E, Attal N. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176: 325–52.
89. Hoong CWS, Amin MNME, Tan TC, Lee JE. Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms. Int J Infect Dis. 2021;104: 363–9.
90. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
91. Li L, Huang T, Wang Y, Wang Z, Liang Y, Huang T, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–83.
92. Azadvari M, Haghparast A, Nakhostin-Ansari A, Emami Razavi SZ, Hosseini M. Musculoskeletal symptoms in patients with long COVID: a crosssectional study on Iranian patients. Heliyon. 2022;8(8): e10148.
93. Bileviciute-ljungar I, Norrefalk J, Borg K. Pain burden in post-COVID-19 syndrome following mild COVID-19 infection. J Clin Med. 2022;11(3):771.
94. Ballering AV, van Zon SKR, Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452–61.
95. Fiala K, Martens J, Abd-Elsayed A. Post-COVID Pain Syndromes. Curr Pain Headache Reports. 2022;26: 379–83.
96. Carfı` A, Bernabei R, Landi F. Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603.
97. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-center longitudinal study. Clin Microbiol Infect. 2021;27:89.
98. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747.
99. Jacobson KB, Rao M, Bonilla H, et al. Patients with uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. Clin Infect Dis. 2021;73(3):e826–9.
100. Sardari A, Tabarsi P, Borhany H, et al. Myocarditis detected after COVID-19 recovery. Eur Heart J Cardiovasc Imaging. 2021;22:131.
101. Vallejo N, Teis A, Mateu L, Genı´s AB. Persistent chest pain after recovery of COVID-19: microvascular disease-related angina? Eur Heart J. 2021.
102. Varatharaj A, Thomas N, Ellul MA, Davies NW, Pollak TA, Tenorio EL, Plant G. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875–82.
103. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.
104. Lowenstein CJ, Solomon SD. Severe COVID-19 Is a microvascular disease. Circulation. 2020;142: 1609–11.
105. Janssens KAM, Rosmalen JGM, Ormel J, van Oort FV, Oldehinkel AJ. Anxiety and depression are risk factors rather than consequences of functional somatic symptoms in a general population of adolescents: the TRAILS study. J Child Psychol Psychiatry. 2010;51:304–12.
106. Scholtens S, Smidt N, Swertz MA, et al. Cohort profile: Lifelines, a three-generation.
107. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):1–22.
108. Iqbal A, Iqbal K, Arshad Ali S, et al. The COVID-19 sequelae: a cross-sectional evaluation of post-recovery symptoms and the need for rehabilitation of COVID-19 survivors. Cureus. 2021.
109. Khoja O, Silva Passadouro B, Mulvey M, Delis I, Astill S, Tan AL, Sivan M. Clinical characteristics and mechanisms of musculoskeletal pain in long COVID. J Pain Res. 2022;17(15):1729–48.
110. Alonso-Matielo H, da Silva Oliveira VR, de Oliveira VT, Dale CS. Pain in COVID Era. Front Physiol. 2021;12: 624154.
111. Abdelnour L, Eltahir Abdalla M, Babiker S. COVID-19 infection presenting as motor peripheral neuropathy. J Formos Med Assoc. 2020;119:1119–20.
112. Ryabkova VA, Churilov LP, Shoenfeld Y. Neuroimmunology: what role for autoimmunity, neuroin- flammation, and small fiber neuropathy in fibromyalgia, chronic fatigue syndrome, and adverse events after human papillomavirus vaccination? Int J Mol Sci. 2019;20:5164.
113. Lichtenstein A, Tiosano S, Amital H. The complexities of fibromyalgia and its comorbidities. Curr Opin Rheumatol. 2018;30:94–100.
114. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O’Connor L, Leavy D, O’Brien K, Dowds J, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of the severity of the initial infection. PLoS One. 2020;15: e0240784.
115. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain. 2016;157:55–64.
116. Slattery BW, Haugh S, O’Connor L, Francis K, Dwyer CP, O’Higgins S, et al. An evaluation of the effectiveness of the modalities used to deliver electronic health interventions for chronic pain: systematic review with network meta-analysis. J Med Internet Res. 2019;21(7): e11086.
117. Areias AC, Costa F, Janela D, Molinos M, Moulder RG, Lains J, Scheer JK, Bento V, Yanamadala V, Correia FD. Long-term clinical outcomes of a remote digital musculoskeletal program: an ad hoc analysis from a longitudinal study with a non-participant comparison group. Healthcare. 2022;10: 2349.
118. Kathleen K. Telemedicine for pain management: where does it stand as we head into 2023? Practical Pain Management 2022; Oct 12, Vol 22, 6.
119. Saucier R. Lowering the threshold: models of accessible methadone and buprenorphine treatment. (2010).
120. Breve F, Batastini L, LeQuang JK, et al. Mobile narcotic treatment programs: on the road again? Cureus. 2022;14(3): e23221.
121. Mikkelsen ME, Abramoff B. COVID-19: evaluation and management of adults with persistent symptoms following acute illness ("Long COVID"). UpToDate Dec 2022; Topic 129312 Version 59.0. Available at:
122. Lee JH, Kim DH, Kim DH, et al. Comparison of clinical efficacy of epidural injection with or without steroid in lumbosacral disc herniation: a systematic review and meta-analysis. Pain Phys. 2018;21(5): 449468.
123. Van Boxem K, Rijsdijk M, Hans G, et al. Safe use of epidural corticosteroid injections: recommendations of the WIP Benelux Work Group. Pain Pract. 2019;19:61–92.
124. Rabinovitch DL, Peliowski A, Furlan AD. Influence of lumbar epidural injection volume on pain relief or radicular leg pain and/or low back pain. Spine J. 2009;9:509–17. 125. Tu¨rkyilmaz GG, Rumeli S. Attitude changes toward chronic pain management of pain physicians in Turkey during the COVID-19 pandemic. Agri. 2022;34(2):77–83.
126. Raff M, Belbachir A, El-Tallawy S, Ho KY, Nagtalon E, Salti A, Seo JH, Tantri AR, Wang H, Wang T, Buemio KC, Gutierrez C, Hadjiat Y. Intravenous oxycodone versus other intravenous strong opioids or acute postoperative pain control: a systematic review of randomized controlled trials. Pain Ther. 2019;8(1):19–39.
127. Page GG. Immunologic effects of opioids in the presence or absence of pain. J Pain Symptom Manage. 2005;29:S25-31.
128. Bianco GL, Papa A, Schatman MEA, et al. Practical advice for treating chronic pain in the time of COVID-19: a narrative review focusing on interventional techniques. J Clin Med. 2021;10:2303.
129. Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol. 2010;66:977–85.
130. Gudin J. Opioid therapies and cytochrome P450 interactions. J Pain Symptom Manag. 2012;44: S4–14.
131. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003;37:476–82.
132. Gibbons JB, Norton EC, McCullough JS, et al. Association between vitamin D supplementation and COVID-19 infection and mortality. Sci Rep. 2022;12:19397.
133. O’Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24: 100485.
134. Natelson B, Blate M, Soto T. Transcutaneous vagus nerve stimulation in the treatment of long COVID chronic fatigue syndrome. medRxiv. 2022.
【For more info:george.deng@wecistanche.com / WhatsApp:8613632399501】
